Latest News

VSTECS Holdings Limited ( HKG:856 ) shareholders (or potential shareholders) will be happy to see that the Group...

Those following along with ANTA Sports Products Limited ( HKG:2020 ) will no doubt be intrigued by the recent purchase...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

CALB Group Co., Ltd. ( HKG:3931 ) shareholders will have a reason to smile today, with the analysts making substantial...

Investors were underwhelmed by the solid earnings posted by Super Hi International Holding Ltd. ( HKG:9658 ) recently...

Investors who take an interest in Greentown Management Holdings Company Limited ( HKG:9979 ) should definitely note...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Amylyx Pharmaceuticals (AMLX) shares are in focus after the company reported that the final participant has been randomized and dosed in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia. See our latest analysis for Amylyx Pharmaceuticals. The latest trial milestone arrives as momentum in Amylyx Pharmaceuticals' share price has been building, with a 7 day share price return of 23.98% and a 90 day share price return of 39.02%, set against a very large 1 year...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

In March 2026, Orezone Gold Corporation reported its fourth-quarter and full-year 2025 results, producing 30,407 ounces of gold in Q4 and 110,014 ounces for the year, slightly below the 118,746 ounces recorded in 2024. At the same time, Orezone issued a much higher 2026 production guidance of 160,000 to 180,000 ounces, highlighting management’s confidence in operational progress despite the softer 2025 output. We’ll now examine how this higher 2026 production guidance reshapes Orezone Gold’s...

Recent analysis of past performance shows that Service Corporation International has not increased the number of funeral services performed over the last two years, while also reporting weaker free cash flow margins and a declining return on invested capital compared with sector expectations. This combination of stagnant service volumes and deteriorating profitability metrics suggests the company may be contending with demand constraints and limited high-return reinvestment...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Helmerich & Payne has completed the sale of Tulsa’s Utica Square retail center, with after-tax proceeds exceeding its US$100 million divestiture target and earmarked largely to retire the company’s remaining term loan as part of a balance sheet-focused portfolio review. The move marks a significant shift away from non-core real estate and frees up financial capacity that can be redeployed toward Helmerich & Payne’s core drilling and technology operations following its capital-intensive KCA...

Acuity (AYI) is back in focus after its second quarter 2026 earnings, where adjusted earnings per share came in ahead of expectations while revenue lagged forecasts, highlighting contrasting trends across its Lighting and Intelligent Spaces businesses. See our latest analysis for Acuity. The share price reaction has been mixed, with a 1 day share price return of 1.06% after earnings but a 90 day share price return representing a 28.55% decline. However, the 3 year total shareholder return of...

Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views. See our latest analysis for Xeris Biopharma Holdings. At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1...

Olin Corporation recently received an upgrade from Wells Fargo, with the firm citing expectations of stronger margins in its electrochemical operations supported by higher caustic soda prices and stable North American natural gas costs. This shift in analyst view highlights how Olin’s earnings outlook is increasingly being tied to both its cost position and evolving global chemical pricing shaped by geopolitical tensions. We’ll now examine how this margin-focused upgrade from Wells Fargo...

Assurant recently reported its ninth consecutive year of profitable growth, highlighted by strong Q4 2025 earnings, record mobile trade-in activity, and the launch of Assurant Home Warranty through a partnership with Compass International Holdings, expanding its reach in the real estate channel. These developments underline how Assurant’s diversified protection offerings and new distribution partnerships are reinforcing its position across connected devices, housing, and broader lifestyle...

China Cinda Asset Management (SEHK:1359) has drawn fresh attention after reporting full year 2025 results that showed higher net income and earnings per share, along with a proposed 2025 cash dividend, both announced on March 31, 2026. See our latest analysis for China Cinda Asset Management. The latest full year results and proposed dividend have landed after a weak stretch for the share price. The 90 day share price return shows a 15.56% decline and the year to date share price return shows...

In recent weeks, Tandem Diabetes Care has faced an extended losing streak and a reduction in its market value, amid investor concerns about its operating performance and financial health. Adding to this pressure, JPMorgan Chase & Co. cut its stake in the company by more than a third, underscoring shifting institutional confidence at a sensitive time. Now we’ll examine how weakening operating performance and JPMorgan’s reduced stake may influence Tandem Diabetes Care’s existing investment...

Despite the fact that HMA Agro Industries Limited (NSE:HMAAGRO) stock rose 14% last week, insiders who sold ₹85m worth...

Recent Performance Snapshot Federal Signal (FSS) has attracted fresh attention after a strong 1 year total return of 55.23%, contrasting with a modest month gain of 0.31% and a 4.72% decline over the past 3 months. See our latest analysis for Federal Signal. The 1 year total shareholder return of 55.23% stands in contrast to the recent 4.72% 3 month share price decline and slightly negative year to date share price return, suggesting that momentum has cooled following a strong multi year...

How Four Corners Property Trust Stock Has Been Performing Four Corners Property Trust (FCPT) has drawn attention after recent trading, with the stock closing at $23.44 and showing mixed return patterns over the past week, month and past 3 months. Over the past day, FCPT recorded a 1.31% decline, with a 1.97% decline across the last week and an 8.72% decline over the past month. The past 3 months have been relatively flat, with a total return of 0.21%. Looking at a slightly longer horizon, the...

In early April 2026, Intellia Therapeutics received an upgrade from Jones Trading after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, restoring regulatory clarity following a patient death deemed likely unrelated to the company’s treatment. This renewed regulatory confidence, alongside expectations for key HAELO Phase 3 data, highlights how safety assessments can critically reshape perceptions of Intellia’s CRISPR pipeline and commercial pathway. With clinical...